Brought to you by 
Atara options exclusive rights to three of Memorial Sloan-Kettering's allogenic T-cell therapy candidates
02 Feb 2023
Executive Summary
While waiting to complete its initial public offering, Atara Biotherapeutics Inc. (developing treatments for cancer and kidney diseases) entered into an option agreement with Memorial Sloan-Kettering Cancer Center for exclusive global development and commercialization rights to three of the institution’s allogenic T-cell therapeutics.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Atara options exclusive rights to three of Memorial Sloan-Kettering's allogenic T-cell therapy candidates
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice